Physician profile
Keith A Bernstein
NPI 1447273727
$4,773.38
in general payments reported to CMS, 2019-2025
44 companies · $840 in 2025
The $840 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $339 · 2021: $699 · 2022: $498 · 2023: $916 · 2024: $898 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $456.89 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $452.74 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $421.72 | 2019-2025 | Saphnelo, Evusheld |
| Janssen Biotech, INC. | $408.11 | 2019-2025 | Tremfya |
| Abbvie INC. | $376.41 | 2020-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $333.50 | 2019-2025 | |
| Lilly USA, LLC | $290.18 | 2019-2025 | Taltz |
| Novo Nordisk INC | $158.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $148.30 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbott Laboratories | $147.07 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $134.59 | 2019-2025 | |
| Ucb, INC. | $116.29 | 2019-2024 | Cimzia |
| Sunovion Pharmaceuticals INC. | $87.07 | 2019 | |
| Genzyme Corporation | $83.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.44 | 2019-2023 | Cyltezo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.